Development of PET radiopharmaceuticals and their clinical applications at the Positron Medical Center

Geriatrics and Gerontology International

Volumn 10, Issue SUPPL. 1, 2010, Pages

  Ishiwata, Kiichi ^a   Kimura, Yuichi ^a,h   Oda, Keiichi ^a   Ishii, Kenji ^a   Sakata, Muneyuki ^a   Kawasaki, Keiichi ^a   Nariai, Tadashi ^b   Suzuki, Yukihisa ^b   Ishibashi, Kenji ^c   Mishina, Masahiro ^d   Hashimoto, Masaya ^e   Ishikawa, Masatomo ^f   Toyohara, Jun ^g  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b Department of Neurosurgery ^*  (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g CHIBA UNIVERSITY   (Japan)

^h NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Aging; Brain function; Positron emission tomography; Radiopharmaceutical; Tumor diagnosis

Indexed keywords

3 METHYLSPIPERONE C 11; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 4 AMINOBUTYRIC ACID A RECEPTOR; 8 DICYCLOPROPYLMETHYL 1,3 DIPROPYLXANTHINE; ACETIC ACID C 11; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; AMYLOID BETA PROTEIN; BENZODIAZEPINE RECEPTOR; CANNABINOID RECEPTOR; CHOLINE C 11; CYCLOOXYGENASE 1; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; FLUMAZENIL C 11; FLUORODEOXYGLUCOSE F 18; GLYCOPROTEIN P; HISTAMINE RECEPTOR; HUMAN SERUM ALBUMIN; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; NITROGEN 13; OXYGEN 15; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; SEROTONIN 5 RECEPTOR; SIGMA OPIATE RECEPTOR; UNINDEXED DRUG; GLUCOSE;

AGING; ALZHEIMER DISEASE; BLOOD FLOW; BLOOD VOLUME; BRAIN; BRAIN BLOOD FLOW; BRAIN FUNCTION; BRAIN TUMOR; CORTICOBASAL DEGENERATION; DEGENERATIVE DISEASE; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; FOCAL EPILEPSY; GERIATRIC DISORDER; GLUCOSE METABOLISM; HEART FUNCTION; HEART MUSCLE BLOOD FLOW; HEMODYNAMICS; HUMAN; INFLAMMATION; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN CONSUMPTION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RECEPTOR BINDING; REVIEW; SHY DRAGER SYNDROME; SKELETAL MUSCLE; TUMOR; METABOLISM; PARKINSONISM; PHYSIOLOGY; SCINTISCANNING; VASCULARIZATION;

ALZHEIMER DISEASE; BRAIN; GLUCOSE; HUMANS; MUSCLE, SKELETAL; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1; RECEPTORS, SIGMA; REGIONAL BLOOD FLOW;

EID: 77954665680     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2010.00594.x     Document Type: Review

References (136)

1. Ito H, Kanno I, Kato C. Database of normal human cerebral blood flow, cerebral blood volume, cerebral oxygen extraction fraction and cerebral metabolic rate of oxygen measured by positron emission tomography with 15O-labelled carbon dioxide or water, carbon monoxide and oxygen: a multicentre study in Japan. Eur J Nucl Med Mol Imaging 2004, 31:635-643.
2. Nariai T, Matsushima Y, Imae S. Severe haemodynamic stress in selected subtypes of patients with moyamoya disease: a positron emission tomography study. J Neurol Neurosurg Psychiatry 2005, 76:663-666.
3. Tanaka Y, Nariai T, Nagaoka T. Quantitative evaluation of cerebral hemodynamics in patients with moyamoya disease by dynamic susceptibility contrast magnetic resonance imaging - comparison with positron emission tomography. J Cereb Blood Flow Metab 2006, 26:291-300.
4. Tatsumi IF, Fushimi T, Sadato N. Verb generation in Japanese - a multicenter PET activation study. NeuroImage 1999, 9:154-164.
5. De Volder AG, Toyama H, Kimura Y. Auditory triggered mental imagery of shape involves visual association areas in early blind humans. NeuroImage 2001, 14:129-139.
6. Suzuki Y, Kiyosawa M, Mochizuki M, Wakakura M, Ishii K, Senda M. Oscillopsia associated with dysfunction of visual cortex. Jpn J Ophthalmol 2004, 48:128-132.
7. Mizoguchi S, Suzuki Y, Kiyosawa M, Mochizuki M, Ishii K. Differential activation of cerebral blood flow by stimulating amblyopic and fellow eye. Graefes Arch Clin Exp Ophthalmol 2005, 243:576-582.
8. Kaga K, Kurauchi T, Nakamura M, Shindo M, Ishii K. Magnetoencephalography and positron emission tomography studies of a patient with auditory agnosia caused by bilateral lesions confined to the auditory radiations. Acta OtoLaryngol 2005, 125:1351-1355.
9. Nariai T, Senda M, Ishii K. Three-dimentional imaging of cortical structure, function and glioma for tumor resection. J Nucl Med 1997, 38:1563-1568.
10. Mishina M, Ishii K, Mitani K. Midbrain hypometabolism as early diagnostic sign for progressive supranuclear palsy. Acta Neurol Scand 2004, 110:128-135.
11. Itokawa K, Tamura N, Kawai N, Shimazu K, Ishii K. Parkinsonism in type I Gaucher's disease. Intern Med 2006, 45:1165-1167.
12. Suzuki Y, Mizoguchi S, Kiyosawa M. Glucose hypermetabolism in the thalamus of patients with essential blepharospasm. J Neurol 2007, 254:890-896.
13. Mishina M. Positron emission tomography for brain research. J Nippon Med Sch 2008, 75:68-76.
14. Mishina M, Ishii K, Kitamura S. Correlation between each task of Mini-Mental State Examination and regional glucose hypometabolism in at-rest Alzheimer's disease patients. Geriatr Gerontol Int 2007, 7:124-130.
15. Kawasaki K, Ishii K, Saito Y, Oda K, Kimura Y, Ishiwata K. Influence of mild hyperglycemia on cerebral 18F-FDG distribution patterns calculated by statistical parametric mapping. Ann Nucl Med 2008, 22:191-200.
16. Elsinga PH, Hatano K, Ishiwata K. PET tracers for imaging of the dopaminergic system. Curr Med Chem 2006, 13:2139-2153.
17. Ishiwata K, Senda M. In vivo binding of [11C]nemonapride to sigma receptors in the cortex and cerebellum. Nucl Med Biol 1999, 26:627-631.
18. Ishibashi K, Ishii K, Oda K, Kawasaki K, Mizusawa H, Ishiwata K. Regional analysis of the age-related decline in dopamine transporters and dopamine D2 receptors in human striatum. Synapse 2008, 63:282-290.
19. Orimo S, Amino T, Tanaka H, Mitani K, Ishiwata K, Ishii K. A case of hemiparkinsonism following ischemic lesion of the contralateral substantia nigra - a PET study. Eur Neurol 2004, 51:175-177.
20. Hashimoto M, Kawasaki K, Suzuki M. Pre- and post-synaptic nigrostriatal dopaminergic functions in multiple system atrophy. Neuroreport 2008, 19:145-150.
21. Saito T, Nakamura M, Shimizu T. Neuroradiologic evidence of pre-synaptic and post-synaptic nigrostriatal dopaminergic dysfunction in idiopathic basal ganglia calcification: a case report. J Neuroimaging 2008, Oct 21; [Epub ahead of print
22. Horie C, Suzuki Y, Kiyosawa M. Decreased dopamine D2 receptor binding in essential blepharospasm. Acta Neurol Scand 2009, 119:49-54.
23. Ohyama M, Senda M, Ishiwata K. Preserved benzodiazepine receptors in Alzheimer's disease measured with C-11 flumazenil PET and I-123 iomazenil SPECT in comparison with CBF. Ann Nucl Med 1999, 13:309-315.
24. Mishina M, Senda M, Kimura Y. Intrasubject correlation between static scan and distribution volume images for [11C]flumazenil PET. Ann Nucl Med 2000, 14:193-198.
25. Mishina M, Senda M, Kiyosawa M. Increased regional cerebral blood flow but normal distribution of GABAA receptor in the visual cortex of subjects with early-onset blindness. Neuroimage 2003, 19:125-131.
26. Ohta Y, Nariai T, Akimoto H. Tuberous sclerosis: epileptogenicity and multimodal presurgical evaluations. Childs Nerv Syst 2001, 17:313-319.
27. Ohta Y, Nariai T, Ishii K. Voxel- and ROI-based statistical analyses of PET parameters for guidance in the surgical treatment of intractable nesial temporal lobe epilepsy. Ann Nucl Med 2008, 22:495-503.
28. Suzuki Y, Horie C, Kiyosawa M. Measurement of the 11C-flumazenil binding in the visual cortex predicts the prognosis of hemianopia. J Neurol Sci 2008, 268:102-107.
29. Ishiwata K, Kawamura K, Wang WF. Evaluation of in vivo selective binding of [11C]doxepin to histamine H1 receptors in five animal species. Nucl Med Biol 2004, 31:493-502.
30. Mochizuki H, Kimura Y, Ishii K. Quantitative measurement of histamine H1 receptors in human brains by PET and [11C]doxepin. Nucl Med Biol 2004, 31:165-171.
31. Mochizuki H, Kimura Y, Ishii K. Simplified PET measurement for evaluating histamine H1 receptors in human brains using [11C]doxepin. Nucl Med Biol 2004, 31:1005-1011.
32. Suzuki A, Tashiro M, Kimura Y. Use of reference tissue models for quantification of histamine H1 receptors in human brain by using positron emission tomography and [11C]doxepin. Ann Nucl Med 2005, 19:425-433.
33. Tashiro M, Mochizuki H, Sakurada Y. Brain histamine H1 receptor occupancy of orally administered antihistamines measured by positron emission tomography with 11C-doxepin in a placebo-controlled crossover study design in healthy volunteers: a comparison of olopatadine and ketotifen. Br J Clin Pharmacol 2006, 61:16-26.
34. Kawamura K, Ishiwata K, Tajima H. In vivo evaluation of [11C]SA4503 as a PET ligand for mapping CNS sigma1 receptors. Nucl Med Biol 2000, 27:255-261.
35. Kawamura K, Ishiwata K, Shimada Y. Preclinical evaluation of [11C]SA4503: radiation dosimetry, in vivo selectivity and PET imaging of sigma1 receptors in the cat brain. Ann Nucl Med 2000, 14:285-292.
36. Kawamura K, Elsinga PH, Kobayashi T. Synthesis and evaluation of 11C- and 18F-labeled 1-[2-(4-alkoxy3-methoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazines as sigma receptor ligands for positron emission tomography studies. Nucl Med Biol 2003, 30:273-284.
37. Elsinga PH, Tsukada H, Harada N. Evaluation of [18F]fluorinated sigma receptor ligands in the conscious monkey brain. Synapse 2004, 52:29-37.
38. Kawamura K, Tsukada H, Shiba K. Synthesis and evaluation of fluorine-18-labeled SA4503 as a selective sigma1 receptor ligand for positron emission tomography. Nucl Med Biol 2007, 34:571-577.
39. Hashimoto K, Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharma Design 2006, 12:3915-3928.
40. Ishiwata K, Kobayashi T, Kawamura K, Matsuno K. Age-related changes of the binding of [3H]SA4503 to sigma1 receptors in the rat brain. Ann Nucl Med 2003, 17:73-77.
41. Kawamura K, Kimura Y, Tsukada H. An increase of sigma1 receptors in the aged monkey brain. Neurobiol Aging 2003, 24:745-752.
42. Ishiwata K, Kawamura K, Kobayashi T, Matsuno K. Sigma1 and dopamine D2 receptors occupancy in the mouse brain after a single administration of haloperidol and two dopamine D2-like receptor ligands. Nucl Med Biol 2003, 30:429-434.
43. Sakata M, Kimura Y, Naganawa M. Mapping of human cerebral sigma1 receptors using positron emission tomography and [11C]SA4503. NeuroImage 2007, 35:1-8.
44. Ishiwata K, Ishii K, Kimura Y. Successive positron emission tomography measurement of cerebral blood flow and neuroreceptors in the human brain: an 11C-SA4503 study. Ann Nucl Med 2008, 22:411-416.
45. Kimura Y, Naganawa M, Shidamara M, Ikoma Y, Watabe H. PET kinetic analysis - Pitfalls and a solution for the Logan plot. Ann Nucl Med 2007, 21:1-8.
46. Kimura Y, Naganawa M, Sakata M. Distribution volume as an alternative to the binding potential for sigma1 receptor imaging. Ann Nucl Med 2007, 21:533-535.
47. Shidahara M, Seki C, Naganawa M. Improvement of likelihood estimation in Logan graphical analysis using maximum A posteriori for neuroreceptor PET imaging. Ann Nucl Med 2009, 23:163-171.
48. Sakata M, Kimura Y, Naganawa M. Shortened protocol in practical [11C]SA4503-PET studies for the sigma1 receptor quantification. Ann Nucl Med 2008, 22:143-146.
49. Mishina M, Ishiwata K, Ishii K. Function of sigma1 receptors in Parkinson's disease. Acta Neurologica Scand 2005, 112:103-107.
50. Mishina M, Ohyama M, Ishii K. Low density of sigma1 receptors in early Alzheimer's disease. Ann Nucl Med 2008, 22:151-156.
51. Ishiwata K, Oda K, Sakata M. A feasibility study of [11C]SA4503-PET for evaluating sigma1 receptor occupancy by neuroleptics: the binding of haloperidol to sigma1 and dopamine D2-like receptors. Ann Nucl Med 2006, 20:569-573.
52. Ishikawa M, Ishiwata K, Ishii K. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a PET study using [11C]SA4503. Biol Psychiatry 2007, 62:878-883.
53. Toyohara J, Sakata M, Ishiwata K. Imaging of sigma1 receptors in the human brain using PET and [11C]SA4503. CNS Agents Med Chem 2009, 9:190-196.
54. van Waarde A, Buursma AR, Hospers GAP. Tumor imaging with 2 σ-receptor ligands, [18F]FE-SA5845 and [11C]SA4503: a feasibility study. J Nucl Med 2004, 45:1939-1946.
55. Kawamura K, Kubota K, Kobayashi T. Evaluation of [11C]SA5845 and [11C]SA4503 for imaging of sigma receptors in tumors by animal PET. Ann Nucl Med 2005, 19:701-709.
56. van Waarde A, Jager PL, Ishiwata K, Dierckx RA, Elsinga PH. Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med 2006, 47:150-154.
57. van Waarde A, Been LB, Ishiwata K, Dierckx RA, Elsinga PH. Early response of s-ligands and metabolic PET tracers to 3 forms of chemotheraphy: an in vitro study in glioma cells. J Nucl Med 2006, 47:1538-1545.
58. van Waarde A, Shiba K, de Jong JR, Ishiwata K, Dierckx RA, Elsinga PH. Rapid reduction of sigma-1 receptor binding and FDG uptake in rat gliomas after in vivo treatment with doxorubicin. J Nucl Med 2007, 48:1320-1326.
59. Rybczynska AA, Elsinga PH, Ishiwata K, Dierckx RA, van Waarde A. Cytotoxicity of sigma receptor ligands is associated with striking changes of cellular metabolism and virtually complete occupancy of the sigma-2 subpopulation. J Nucl Med 2008, 49:2049-2056.
60. Rybczynska AA, Elsinga PH, Sijbesma JW. Steroid hormones affect binding of the sigma ligand 11C-SA4503 in tumor cells and tumor-bearing rats. Eur J Nucl Med Mol Imaging 2009, 36:1167-1175.
61. Ishiwata K, Takai H, Nonaka H, Ishii S, Shimada J, Senda M. Synthesis and preliminary evaluation of a carbon-11-labeled adenosine transporter blocker [11C]KF21652. Nucl Med Biol 2001, 28:281-285.
62. Suzuki F, Ishiwata K. Selective adenosine antagonists for mapping central nervous system adenosine receptors with positron emission tomography: carbon-11 labeled KF15372 (A1) and KF17837 (A2A). Drug Develop Res 1998, 45:312-323.
63. Ishiwata K, Shimada J, Ishii K, Suzuki F. Assessment of adenosine A2A receptors with PET as a new diagnostic tool for neurological disorders. Drugs Future 2002, 27:569-576.
64. Ishiwata K, Kimura Y, de Vries EFJ, Elsinga PH. PET tracers for mapping adenosine receptors as probes for diagnosis of CNS disorders. CNS Agents Med Chem 2007, 7:57-77.
65. Bauer A, Ishiwata K. Adenosine receptor ligands and PET imaging of the CNS. Handbook for Experimental Pharmacology 2009, 617-478. Wilson CN, Mustafa SJ. eds., Vol. 200, Berlin-Heidelberg, Springer-Verlag
66. Furuta R, Ishiwata K, Kiyosawa M. Carbon-11 labeled KF15372: a potential central nervous system adenosine A1 recepter ligand. J Nucl Med 1996, 37:1203-1207.
67. Noguchi J, Ishiwata K, Furuta R. Evaluation of carbon-11C labeled KF15372 and it's ethyl and methyl derivatives as a potential CNS adenosine A1 receptor ligand. Nucl Med Biol 1997, 24:53-59.
68. Wakabayashi S, Nariai T, Ishiwata K. A PET study of adenosine A1 receptor in anesthetized monkey brain. Nucl Med Biol 2000, 27:401-406.
69. Kiyosawa M, Ishiwata K, Noguchi J. Neuroreceptor bindings and synaptic activity in visual system of monocularly enucleated rat. Jpn J Ophthalmol 2001, 45:264-269.
70. Wang WF, Ishiwata K, Kiyosawa M, Shimada J, Senda M, Mochizuki M. Adenosine A1 and benzodiazepine receptors and glucose metabolism in the visual structures of rats monocularly deprived by enucleation or eyelid suture at a sensitive period. Jpn J Ophthal 2003, 47:182-190.
71. Nariai T, Shimada Y, Ishiwata K. PET imaging of adenosine A1 receptors with C-11 MPDX as an indicator of severe cerebral ischemic insult. J Nucl Med 2003, 44:1839-1844.
72. Nariai T, Shimada Y, Ishiwata K. PET neuroreceptor imaging as predictor of severe cerebral ischemic insult. Acta Neurochir Suppl 2003, 86:45-48.
73. Ishiwata K, Nariai T, Kimura Y. Preclinical studies on [11C]MPDX for mapping adenosine A1 receptors by positron emission tomography. Ann Nucl Med 2002, 16:377-382.
74. Fukumitsu N, Ishii K, Kimura Y. Imaging of adenosine A1 receptors in the human brain by positron emission tomography with [11C]MPDX. Ann Nucl Med 2003, 17:511-515.
75. Kimura Y, Ishii K, Fukumitsu N. Quantitative analysis of adenosine A1 receptors in human brain using positron emission tomography and [1-methyl-11C]8-dicyclopropylmethyl-1-methyl-3-propylxanthine. Nucl Med Biol 2004, 31:975-981.
76. Fukumitsu N, Ishii K, Kimura Y. Adenosine A1 receptor mapping of the human brain by positron emission tomography with [11C]MPDX. J Nucl Med 2005, 46:32-37.
77. Fukumitsu N, Ishii K, Kimura Y. Adenosine A1 receptors using 8-dicyclopropylmethyl-1-[11C]methyl-3-propylxanthine PET in Alzheimer's disease. Ann Nucl Med 2008, 22:841-847.
78. Ishiwata K, Noguchi J, Wakabayashi S. Carbon-11 labeled KF18446, a potential CNS adenosine A2A receptor ligand. J Nucl Med 2000, 41:345-354.
79. Ishiwata K, Ogi N, Shimada J. Further characterization of a CNS adenosine A2A receptor ligand [11C]KF18446 with in vitro autoradiography and in vivo tissue uptake. Ann Nucl Med 2000, 14:81-89.
80. Ishiwata K, Ogi N, Hayakawa N. Adenosine A2A receptor imaging with [11C]KF18446 PET in the rat brain following quinolinic acid lesion: comparison with the dopamine receptor imaging. Ann Nucl Med 2002, 16:467-475.
81. Ishiwata K, Ogi N, Shimada J. Search for PET probes for imaging the globus pallidus studied with rat brain ex vivo autoradiography. Ann Nucl Med 2000, 14:461-466.
82. Ishiwata K, Wang WF, Kimura Y, Kawamura K, Ishii K. Preclinical studies on [11C]TMSX for mapping adenosine A2A receptors by positron emission tomography. Ann Nucl Med 2003, 17:205-211.
83. Ishiwata K, Mishina M, Kimura Y, Oda K, Sasaki T, Ishii K. First visualization of adenosine A2A receptors in the human brain by positron emission tomography with [11C]TMSX. Synapse 2005, 55:133-136.
84. Naganawa M, Kimura Y, Mishina M. Quantification of adenosine A2A receptors in normal human brain measured with [11C]TMSX and positron emission tomography. Eur J Nucl Med Mol Imaging 2007, 34:679-687.
85. Mishina M, Ishiwata K, Kimura Y. Evaluation of distribution of adenosine A2A receptors in normal human brain by [11C]TMSX PET. Synapse 2007, 61:778-784.
86. Mishina M, Ishii K, Kitamura S. Relationship between dopamine D2 and adenosine A2A receptors in drug naive Parkinson's disease using TMSX PET. Mov Disord 2006, 21(15):S622.
87. Hashimoto K, Nishiyama S, Ohba H. [11C]CHIBA-1001 as a novel PET ligand for α7 nicotinic receptors in the brain: a PET study in conscious monkeys. PLoS ONE 2008, 3:e3231.
88. Toyohara J, Sakata M, Ishikawa M. Preclinical and the first clinical studies on [11C]CHIBA-1001 for mapping α7 nicotinic receptors by positron emission tomography. Ann Nucl Med 2009, 23:301-309.
89. Shiba K, Ogawa K, Ishiwata K, Yajima K, Mori H. Synthesis and binding affinities of methylvesamicol analogs for the acetylcholine transporter and sigma receptor. Bioorg Med Chem 2006, 14:2620-2606.
90. Kawamura K, Shiba K, Tsukada H, Nishiyama S, Mori H, Ishiwata K. Synthesis and evaluation of vesamicol analog (-)-o-[11C]methylvesamicol as a PET ligand for vesicular acetylcholine transporter. Ann Nucl Med 2006, 20:417-424.
91. Shiba K, Nishiyama S, Tsukada H. The potential of (-)-o-[11C]methylvesamicol for diagnosing cholinergic deficit dementia. Synapse 2009, 63(2):167-171.
92. Ishiwata K, Kawamura K, Yajima K, QingGeLeTu, Mori H, Shiba K. Evaluation of (+)-p-[11C]methylvesamicol for mapping sigma1 receptors: a comparison with [11C]SA4503. Nucl Med Biol 2006, 33:543-548.
93. Tobiishi S, Sasada T, Nojiri Y. Methoxy- and fluorine-substituted analogs of O-1302: synthesis and in vitro binding affinity for the CB1 cannabinoid receptor. Chem Pharm Bull 2007, 55:1213-1217.
94. Nojiri Y, Ishiwata K, QingGeLeTu. Radiosynthesis and biodistribution of a18F-labeled analog of O-1302 for use in cerebral CB1 cannabinoid receptor imaging. Biol Pharm Bull 2008, 31:1274-1278.
95. Ishiwata K, Kawamura K, Yanai K, Hendrikse NH. In vivo evaluation of P-glycoprotein modulation of eight PET radioligands used clinically. J Nucl Med 2007, 48:81-87.
96. Fujisaki Y, Kawamura K, Wang WF. Radiosynthesis and in vivo evaluation of 11C-labeled 1,5-diarylpyrazole derivatives for mapping cyclooxygenases. Ann Nucl Med 2005, 19:617-625.
97. Tanaka M, Fujisaki Y, Kawamura K. Radiosynthesis and evaluation of 11C-labeled diaryl-substituted Imidazole and indole derivatives for mapping cyclooxygenase-2. Biol Pharm Bull 2006, 29:2087-2094.
98. Kimura Y, Hsu H, Toyama H, Senda M, Alpert NM. Improved signal-to-noise ratio in parametric images by cluster analysis. Neuroimage 1999, 9:554-561.
99. Kimura Y, Naganawa M, Yamaguchi J. MAP-based kinetic analysis for voxel-by-voxel compartment model estimation: detailed imaging of the cerebral glucose metabolism using FDG. NeuroImage 2006, 29:1203-1211.
100. Naganawa M, Kimura Y, Ishii K, Oda K, Ishiwata K, Matani A. Extraction of a plasma time-activity curve from dynamic brain PET images based on independent component analysis. IEEE Trans Biomed Eng 2005, 52:201-210.
101. Naganawa M, Kimura Y, Nariai T. Omission of serial arterial blood sampling in neuroreceptor imaging with independent component analysis. NeuroImage 2005, 26:885-890.
102. Naganawa M, Kimura Y, Ishii K, Oda K, Ishiwata K. Temporal and spatial blood information estimation using Bayesian ICA in dynamic cerebral positron emission tomography. Dig Sig Proc 2007, 17:979-993.
103. Naganawa M, Kimura Y, Yano J. Robust estimation of the arterial input function for Logan plots using an intersectional searching algorithm and clustering in positron emission tomography for neuroreceptor imaging. NeuroImage 2008, 40:26-34.
104. Ishiwata K. Basic concept of 11C-labeled radiopharmaceuticals. RinshouHoushasen (Jpn J Clin Radiol) 2006, 51:801-806. In Japanese
105. Toyohara J, Ishiwata K. PET radiopharmaceuticals for tumor imaging. RinshoGazo (Clin Imagiology) 2007, 23:20-27. In Japanese
106. Kubota K, Furumoto S, Iwata R, Fukuda H, Kawamura K, Ishiwata K. Comparison of 18F-fluoromethylcholine and 2-deoxy-D-glucose in the distribution of tumor and inflammation. Ann Nucl Med 2006, 20:527-533.
107. Ishiwata K, Liu H, Teramoto K, Kawamura K, Oda K, Arii S. Tumor viability evaluation by positron emission tomography with [18F]FDG in the liver metastasis rat model. Ann Nucl Med 2006, 20:463-469.
108. Liu H, Teramoto K, Kawamura K, Oda K, Ishiwata K, Arii S. Evaluation of tumor growth in vivo in a rat model of liver metastasis, using a newly devised index obtained by positron emission tomography with [18F]FDG. J Hepatobiliary Pancreat Surg 2007, 14:276-282.
109. Ohta Y, Nariai T, Ishii K. Meningio-angiomatosis in a patient with focal epilepsy: value of PET in diagnoses and preoperative planning of surgery. Acta Neurochir (Wien) 2003, 145:587-591.
110. Maehara T, Nariai T, Arai N. Usefulness of [11C]methionine PET in the diagnosis of dysembryoplastic neuroepithelial tumor with temporal lobe epilepsy. Epilepsia 2004, 45:41-45.
111. Nariai T, Sato K, Hirakawa K. Imaging of somatotopic representation of sensory cortex with intrinsic optical signals as guides for brain tumor surgery. J Neurosurg 2005, 103:414-423.
112. Nariai T, Tanaka Y, Wakimoto H. Usefulness of L-[methyl-11C]methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 2005, 103:498-507.
113. Tanaka Y, Nariai T, Momose T. Glioma surgery using a multimodal navigation system with integrated metabolic images. J Neurosurg 2009, 110:163-172.
114. Nojiri T, Nariai T, Aoyagi M. Contributions of biological tumor parameters to the incorporation rate of L-[methyl-11C]methionine into astrocytomas and oligodendrogliomas. J Neuro-Oncol 2009, 93:233-241.
115. Ishiwata K, Kubota K, Murakami M. Re-evaluation of amino acid-PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med 1993, 34:1936-1943.
116. Iwata R, Furumoto S, Pascali C, Bogni A, Ishiwata K. Radiosynthesis of O-[11C]methyl-L-tyrosine and O-[18F]fluoromethyl-L-tyrosine as potential PET tracers for imaging amino acid transport. J Labelled Comp Radiopharm 2003, 46:555-566.
117. Ishiwata K, Kawamura K, Wang WF. Evaluation of O-[11C]methyl-L-tyrosine and O-[18F]fluoromethyl-L-tyrosine as tumor imaging tracers by PET. Nucl Med Biol 2004, 31:191-198.
118. Ishikawa Y, Iwata R, Furumoto S. Simple automated preparation of O-[11C]methyl-L-tyrosine for routine clinical use. Appl Radiat Isot 2005, 63:55-61.
119. Ishiwata K, Tsukada H, Kubota K. Preclinical and clinical evaluation of O-[11C]methyl-L-tyrosine for tumor imaging by positron emission tomography. Nucl Med Biol 2005, 32:253-262.
120. Ishiwata K, Kubota K, Nariai T, Iwata R. Whole-body tumor imaging: O-[11C]methyl-L-tyrosine/positron emission tomography. Cancer Imaging 2008, 175-179. Hayat MA, ed., Vol. 2: Instrumentation and Application, San Diego, Elsevier
121. Ishiwata K, Shiono M, Kubota K. A unique iv vivo assessment of 4-[10B]borono-L-phenylalanine in tumour tissues for boron neutron capture therapy of malignant melanoma using positron emission tomography and 4-borono-2-[18F]fluoro-L-phenylalanine. Melanoma Res 1992, 2:171-179.
122. Nariai T, Ishiwata K, Kimura Y. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma. Appl Radiation Isotopes 2009, 67(7-9):S348-350. Suppl
123. Oda K, Toyama H, Mashima Y. A statistical clustering approach to visualizing the relationship between early and delayed images in whole-body FDG-PET. Radiol Phy Tech 2009, 2:145-150.
124. Toyohara J, Okada M, Toramatsu C, Suzuki K, Irie T. Feasibility studies of 4¢-[methyl-11C]thiothymidine as a tumor proliferation imaging agent in mice. Nucl Med Biol 2008, 35:65-72.
125. Ishiwata S, Maruno H, Senda M, Toyama H, Nishiyama S, Seki A. Mechanical efficiency in hypertrophic cardiomyopathy assessed by positron emission tomography with carbon 11 acetate. Am Heart J 1997, 133:497-503.
126. Ishiwata S, Maruno H, Senda M, Toyama H, Nishiyama S, Seki A. Myocardial blood flow and metabolism in patients with hypertrophic cardiomyopathy - a study with carbon-11 acetate and positron emission tomography. Jpn Circ J 1997, 61:201-210.
127. Ishiwata K, Sakiyama Y, Sakiyama T. Myocardial adenosine A2a receptor imaging of rabbit by PET with [11C]KF17837. Ann Nucl Med 1997, 11:219-225.
128. Ishiwata K, Mizuno M, Kimura Y. Potential of [11C]TMSX for evaluation of adenosine A2A receptors in the skeletal muscle by positron emission tomography. Nucl Med Biol 2004, 31:949-956.
129. Mizuno M, Kimura K, Tokizawa K. Greater adenosine A2A receptor densities in cardiac and skeletal muscle in endurance trained men: a [11C]TMSX PET study. Nucl Med Biol 2005, 32:831-836.
130. Mizuno M, Kimura Y, Iwakawa T. Regional differences in blood flow and oxygen consumption in resting muscle and their relationship during recovery from exhaustive exercise. J Appl Physiol 2003, 95:2204-2210.
131. Mizuno M, Kimura Y, Iwakawa T. Regional differences in blood flow and blood transit time in resting skeletal muscle. Jpn J Physiol 2003, 53:467-470.
132. Shimada H, Kimura Y, Suzuki K. The use of positron emission tomography and [18F]fluorodeoxyglucose for functional imaging of muscular activity during exercise with a stride assistance system. IEEE Trans Neuro Rehab Eng 2007, 15:442-448.
133. Shimada H, Suzuki T, Kimura Y. Effects of an automated stride assistance system on walking parameters and muscular glucose metabolism in elderly adults. Br J Sports Med 2008, 42:622-629.
134. Shimada H, Kimura Y, Lord SR. Comparison of regional lower limb glucose metabolism in older adults during warking. Scand J Med Sci Sports 2009, 19:389-397.
135. Kobayashi Y, Ishii K, Oda K. Aortic wall inflammation due to Takayasu arteritis imaged with 18F-FDG PET co-registered with enhanced CT. J Nucl Med 2005, 46:917-922.
136. Maeda Y, Oguni H, Saitou Y. Rasmussen's syndrome: multifocal spread of inflammation suggested from the MRI and PET findings. Epilepsia 2003, 44:1118-1121.